EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...
Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.
The campaign remains ongoing as part of Exact’s health equity efforts, with its respective English- and Spanish-language websites still offering a range of information about colon cancer screening.
Shares of Exact Sciences (NASDAQ:EXAS) gained on Wednesday after the maker of the Cologuard stool-based cancer test announced plans to release data from a blood-based cancer test on Sept.
Act may prescribe an umbrella framework for companies on consent management instead of issuing exact rules, sources in the know told ET. The rules may provide certain exemptions to schools, colleges, ...